Bellicum Pharmaceuticals Overview
- Founded
- 2004

- Status
- Public
- Employees
- 107

- Stock Symbol
- BLCM

- Share Price
- $4.17
- (As of Friday Closing)
Bellicum Pharmaceuticals General Information
Description
Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. Its research areas are cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases. The company's expertise is based on the inclusion of powerful molecular switches planned to eliminate, reduce, or activate therapeutic cells to increase efficacy and safety compared with existing cell therapies. Its pipeline portfolio includes adjunct T-cell therapy (Rivo-cel) to treat leukemias, lymphomas, and genetic blood diseases; CAR T cells technology (BPX-601) to treat prostate, pancreatic, bladder, esophagus, and gastric cancers; and BCMA GoCAR-NK the program targeting B-cell maturation antigen.
Contact Information
- 2710 Reed Road
- Suite 160
- Houston, TX 77030
- United States
Bellicum Pharmaceuticals Stock Performance
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$4.17 | $4.31 | $2.62 - $22.50 | $25.4M | 6.1M | 513K | -$11.07 |
Bellicum Pharmaceuticals Financials Summary
In Thousands, USD |
TTM 30-Sep-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
---|---|---|---|---|
EV | 16,348 | 27,231 | 49,616 | 197,522 |
Revenue | 5,133 | 7,143 | 1,120 | 185 |
EBITDA | (49,112) | (101,042) | (88,778) | (85,598) |
Net Income | (55,486) | (112,477) | (98,036) | (91,779) |
Total Assets | 60,493 | 116,250 | 121,501 | 135,528 |
Total Debt | 29,053 | 38,035 | 35,963 | 35,108 |
Bellicum Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Bellicum Pharmaceuticals‘s full profile, request access.
Request a free trialBellicum Pharmaceuticals Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
This information is available in the PitchBook Platform. To explore Bellicum Pharmaceuticals‘s full profile, request access.
Request a free trialBellicum Pharmaceuticals Comparisons
Industry
0000000
0000 000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialBellicum Pharmaceuticals Competitors (24)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Affimed Therapeutics | Formerly VC-backed | Heidelberg, Germany | 000 | 00000 | 00000000000 | 00000 |
0000 000000000000 | Venture Capital-Backed | Houston, TX | 00 | 00000 | 0000000000 0 | 00000 |
000000 | Venture Capital-Backed | Utrecht, Netherlands | 00 | 00.000 | 000000000000 | 00.000 |
0000000 0000000000 | Venture Capital-Backed | Philadelphia, PA | 00 | 00000 | 00000000000 | 00000 |
0000 000000000000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 00000000 | 00000 |
Bellicum Pharmaceuticals Executive Team (15)
Bellicum Pharmaceuticals Board Members (11)
Name | Representing | Role | Since |
---|---|---|---|
James Brown | AVG Ventures | Chairman & Board Member | 000 0000 |
James Daly | Self | Board Member | 000 0000 |
Jon Stonehouse | Self | Board Member | 000 0000 |
Judith Klimovsky | Self | Board Member | 000 0000 |
Reid Huber Ph.D | Self | Board Member | 000 0000 |
Bellicum Pharmaceuticals Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialBellicum Pharmaceuticals Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Bellicum Pharmaceuticals‘s full profile, request access.
Request a free trial